Dronedarone: Is it time to turn it down?

Expert Opinion on Drug Safety

Volumn 12, Issue 1, 2013, Pages 5-8

  Lin, Li ^a   Bai, Rong ^a,b,c  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Dronedarone; Efficacy; Safety

Indexed keywords

DRONEDARONE;

ANTIARRHYTHMIC ACTIVITY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HEART ATRIUM FIBRILLATION; HUMAN; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SINUS RHYTHM;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CATHETER ABLATION; HUMANS; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84871488121     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2013.742062     Document Type: Review

References (15)

1. Hohnloser SH, Crijns HJJ, van Eickels M, et al. Effect of Dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668-78
2. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31:2369 -429
3. Food and Drug Administration. FDA Drug Safety Communication: severe liver injury associated with the use of Dronedarone (marketed as Multaq). Available from: http://www.fda.gov/Drugs/DrugSafety/ucm240011.htm [Accessed August 23 2012]
4. Food and Drug Administration.Labeling revision: highlights of prescribing information (Multaq). Available from: http://www.accessdata. fda.gov/drugsatfda-docs/label/2012/022425s002lbl.pdf [Accessed August 23 2012]
5. Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268 -76
6. European Medicines Agency. European Medicines Agency recommends restricting use of Multaq. Available from: http://www.ema.europa.eu/ema/index. jsp? curl=pages/news-and-events/news/2011/09/news-detail-001344. jsp&mid=WC0b01ac058004d5c1 [Accessed August 23 2012]
7. De Ferrari GM, Dusi V. Drug safety evaluation of Dronedarone in atrial fibrillation. Expert Opin Drug Safe 2012;11(6):1023 -45
8. Brundel BJ, Van Gelder IC, Henning RH, et al. Alterations in potassium channel gene expression in atria of patients with persistent and paroxysmal atrial fibrillation: differential regulation of protein and mRNA levels for K+ channels. J Am Coll Cardiol 2001;37:926 -32
9. Chatterjee S, Ghosh J, Lichstein E, et al. Meta-Analysis of cardiovascular outcomes with Dronedarone in patients with atrial fibrillation or heart failure. Am J Cardiol 2012;110:607 -13
10. Chiang CE, Naditch-Br^ulé L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol 2012;5:632 -9
11. Parvez B, Vaglio J, Rowan S, et al. Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. J Am Coll Cardiol 2012;60:539 -45
12. European Medicine Agency: assessment report for MULTAQ. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Assessment- Report-Variation/human/001043/WC500121610.pdf [Accessed August 23 2012]
13. Akerborg O, Nilsson J, Bascle S, et al.Cost-effectiveness of Dronedarone in atrial fibrillation: results for Canada, Italy, Sweden, and Switzerland. Clin Ther 2012;34:1788 -802
14. Burashnikov A, Belardinelli L, Antzelevitch C. Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone. J Pharmacol Exp Ther 2012;340:161 -8
15. Mullard A. Second chance for Dronedarone after recent setback? Lancet 2012;379:601